Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial

Published:2015-01-04 Issue:3 Volume:21 Page:775-782
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Vrdoljak Eduard,Géczi Lajos,Mardiak Jozef,Ciuleanu Tudor-Eliade,Leyman Sophie,Zhang Ke,Sajben Peter,Torday Laszlo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12253-014-9889-0.pdf

Reference27 articles.

1. Mena AC, Pulido EG, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anti-Cancer Drugs 21 Suppl. 1: S3-S11. doi: 10.1097/01.cad.0000361534.44052.c5

2. Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V (2012) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(7):vii65–vii71. doi: 10.1093/annonc/mds227

3. Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J (2011) ICUD-EAU International consultation on kidney cancer 2010: treatment of metastatic disease. Eur Urol 60(4):684–690. doi: 10.1016/j.eururo.2011.06.017

4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi: 10.1056/NEJMoa065044

5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi: 10.1200/JCO.2008.20.1293

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Looking into the toxicity potential and clinical benefits of tyrosine kinase inhibitors (TKIs);Reference Module in Biomedical Sciences;2022

2. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis;Future Oncology;2019-06

3. Traitement des métastases osseuses du cancer du rein;Bulletin du Cancer;2018-12

4. Treating patients with renal cell carcinoma and bone metastases;Expert Review of Anticancer Therapy;2018-09-13

5. Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction;Cancer Chemotherapy and Pharmacology;2018-05-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3